These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2865856)

  • 1. [Adjuvant chemotherapy in breast cancer. Report and commentary on the NIH Consensus Development Conference, Bethesda, Maryland, U.S. 9-11 September, 1985].
    Jakesz R
    Wien Klin Wochenschr; 1985 Nov; 97(21):825-7. PubMed ID: 2865856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer--a commentary.
    Lippman ME
    Breast Cancer Res Treat; 1985; 6(3):195-200. PubMed ID: 3841498
    [No Abstract]   [Full Text] [Related]  

  • 3. Consensus conference. Adjuvant chemotherapy for breast cancer.
    JAMA; 1985 Dec; 254(24):3461-3. PubMed ID: 4068189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National Institutes of Health Consensus Development Conference Statement: Adjuvant Chemotherapy for Breast Cancer. September 9-11, 1985.
    CA Cancer J Clin; 1986; 36(1):42-7. PubMed ID: 3080207
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant chemotherapy of breast cancer--the Consensus Development Conference revisited.
    Abeloff MD; Beveridge RA
    Oncology (Williston Park); 1988 Apr; 2(4):21-6, 29-33. PubMed ID: 3079325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on September 1985 NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer.
    Greenspan EM
    Cancer Invest; 1986; 4(5):471-5. PubMed ID: 3542143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid receptors in breast cancer: an NIH Consensus Development Conference, Bethesda, Maryland, June 27-29, 1979.
    Cancer; 1980 Dec; 46(12 Suppl):2759-963. PubMed ID: 6108798
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
    Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
    J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adjuvant chemotherapy of breast cancer: an international review and the Swiss experience].
    Senn HJ
    Arch Geschwulstforsch; 1986; 56(6):425-33. PubMed ID: 3548640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of axillary lymph node metastasis in primary breast cancer.
    Jatoi I; Hilsenbeck SG; Clark GM; Osborne CK
    J Clin Oncol; 1999 Aug; 17(8):2334-40. PubMed ID: 10561295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIH consensus-development statement. Adjuvant chemotherapy of breast cancer. The NIH Consensus-Development Panel.
    N Engl J Med; 1980 Oct; 303(14):831-2. PubMed ID: 6997737
    [No Abstract]   [Full Text] [Related]  

  • 15. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
    Orr RK; Col NF; Kuntz KM
    Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T1a and T1b breast cancer: a twelve-year experience.
    Visser TJ; Haan M; Keidan R; Lucas R; Ingold J; Glover J; Riggo P
    Am Surg; 1997 Jul; 63(7):621-6. PubMed ID: 9202537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.